Coronavirus R&D Gets $3.1 Billion in Emergency Funding

U.S. lawmakers passed a $8.3 billion emergency supplemental bill to fund the federal coronavirus response that includes $3.1 billion for developing diagnostics, vaccines and other medical countermeasures.

The bill allocated $61 million to the FDA to “facilitate the development and review, both pre-market and post-market, of medical countermeasures, devices, therapies, and vaccines.”

It also included approximately $500 million for procurement of masks, personal protective equipment, pharmaceuticals and other medical supplies for distribution to state and local health agencies in areas with a shortage of supplies.